Trial Profile
A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer (PALPETBIO)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms PALPETBIO
- 26 Jun 2018 New trial record